Biowaivers Proposed For Highly Permeable, Soluble, Rapidly Dissolving Drugs
Executive Summary
FDA is proposing to grant waivers of in vivo bioequivalence tests for certain immediate-release solid oral dosage form drugs that meet the characteristics of being highly permeable, soluble and having rapid dissolution.